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An Action Plan for Federal Agencies
Executive Summary
Bisphenol-A (BPA) is a ubiquitous industrial chemical found in everything from baby 
bottles to cash register receipts.  From its inauspicious creation in the laboratory by a group 
of scientists trying to synthesize an estrogenic compound for the pharmaceutical industry, 
it has become a fundamental building block of the multi-billion dollar plastics industry.1  
Unfortunately, ever since anomalous results appeared in two research labs using BPA-
containing plastic equipment in the 1980s, evidence of the chemical’s toxicological risks has 
continued to mount.  The chemical is an endocrine disruptor, meaning that it interferes with 
the body’s hormone system, and BPA’s health risks include, but are not limited to, increased 
susceptibility to prostate and breast cancers,2 reproductive system defects and abnormalities,3 
hormonal imbalances,4 brain development abnormalities,5 gender confusion,6 heart disease,7 
and diabetes.8  Particularly alarming is the evidence that the populations most in danger of 
suffering from BPA’s health risks are fetuses, infants, and children.  New scientific evidence 
about BPA also indicates that the familiar concept of “the dose makes the poison” – an 
idea that underlies most of our federal laws for managing toxic risks – may not apply to 
BPA.  Ordinarily, decreasing exposure to a toxic chemical decreases adverse effects.  Thus 
we manage toxic risks by reducing exposures to a point where health effects do not occur 
or where the risks are sufficiently low that we consider the exposures “safe.”  With BPA, 
however, low doses could cause significant harm, and for certain health effects it appears that 
low dose exposures to BPA could actually be more harmful than some high dose exposures.9
Mounting health and safety concerns over BPA have not only raised consumer anxieties over 
the prolific chemical’s presence, but also given rise to a deceptive consumer environment, 
in which seemingly reassuring labels of “BPA-Free” offer little meaningful information, 
protection, or indication of regulatory progress.  For one thing, substitutes for the chemical, 
such as Bisphenol-S (BPS), may be just as risky.  For another, federal agencies have not taken 
effective steps to control BPA exposures.  To assist the federal agencies in moving forward 
with BPA regulation and to provide the public with a more informative and safer consumer 
environment, this white paper outlines various short-term and long-term regulatory options 
for protecting the public from the health risks posed by BPA.
The Food and Drug Administration (FDA), the Environmental Protection Agency 
(EPA), and the Occupational Safety and Health Administration (OSHA) are the federal 
agencies best situated to tackle BPA risk assessment and risk management, given the 
present state of scientific information on the endocrine-disrupting chemical, the agencies’ 
regulatory authority, and their resources.  This white paper urges a two-phase approach 
to BPA regulation.  The first phase should produce immediate information collection and 
dissemination, including early warnings for the public and stricter guidance for industry.  
The second phase should include long-term regulatory controls, standards, and protections, 
to be promulgated as soon as missing information becomes available.
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Protecting the Public from BPA:
Federal Agency Short-Term  
and Long-Term Action Plan
FDA:  Short-Term  
Regulatory Options
FDA:  Long-Term  
Regulatory Options
Aggressively Pursue Additional 
Scientific Study and Data  
Collection Efforts
FDA should continue with its intentions 
to perform collaborative research projects 
with the National Center for Toxicological 
Research and the National Toxicology 
Program.  In conjunction with these  
efforts, FDA should use its authority  
under the Food Contact Substance 
Notification program to issue new 
guidance on BPA-specific safety testing  
and data submission requirements.
Issue “BPA-Free” Labeling Guidance
FDA should issue labeling guidance  
on the use of “BPA-Free” labels.   
Included in this guidance should be  
a recommendation that any “BPA-Free” 
labeled product that merely uses a 
replacement endocrine-disrupting product 
would be considered misbranded.
Issue New Guidance for Food  
Contact Substance Notification 
Applicants that Imposes Safer  
BPA Use Standards
Issue guidance stating that any new  
Food Contact Substance Notification 
Applicants applying for a new BPA use 
will most likely face denial if the new use 
involves contact with certain foods, such 
as infant formula, or a dangerous target 
consumer, such as children.
Rewrite Redbook Protocols for BPA 
and other Endocrine Disruptors
BPA and other endocrine disrupting 
chemicals do not fit the traditional risk 
assessment mold and thus the underlying 
scientific protocols must be rewritten to 
account for their unique low-dose adverse 
affects and expand study endpoints.
Revoke Existing and New BPA Uses 
Approved under the Food Contact 
Substance Notification Process
Since 2002, packaging uses of BPA have 
been approved under the Food Contact 
Substance Notification process.  FDA 
should revoke approved Food Contact 
Substance Notifications and affirmatively 
deny any new Food Contact Substance 
Notification applications with the aim of 
imposing new safety testing, exposure,  
and use standards.10
Issue New Regulations for BPA Uses
Beginning in 1958, FDA approved certain 
uses of BPA as indirect food additives.  FDA 
has the power to issue new regulations 
prescribing the conditions under which 
those uses are deemed safe.11 FDA 
should utilize this authority and issue 
new regulations outlining specific use 
and safety parameters for BPA.  These 
parameters could be as broad as banning 
specific BPA uses, mandating BPA labeling, 
or mandating the submission of specific 
toxicity and exposure testing information 
on a regular basis.
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EPA: Short-Term  
Regulatory Options
EPA:  Long-term  
Regulatory Options
Update the Existing IRIS Database  
to Accurately Reflect BPA’s Known 
Risks and Datapoints
EPA needs to update its BPA IRIS entry to 
accurately reflect the currently known low-
dose exposure risks.
Utilize TSCA to Gather  
Exposure and Use Information
EPA should aggressively pursue 
development of its proposed BPA Test Rule 
and Chemicals of Concern list.  Resulting 
data collection efforts and studies should 
include both environmental and human 
health risk assessments.  
Managing Risks through Rule 
Development Under TSCA § 6
Utilizing current risk assessment 
information and future exposure data, 
EPA should consider promulgating BPA 
regulatory safeguards, such as warning 
labels, specific use restrictions,  
and a potential ban.
OSHA:  Short-term  
Regulatory Options
OSHA:  Long-term  
Regulatory Options
Assess Workplace Risks  
Through Increased Scientific 
Research and Data Collection
NIOSH and OSHA need to perform more 
U.S. workplace studies and develop a more 
comprehensive database of workplace 
exposures and risks.
Assess & Manage Workplace  
Risks through the Hazard 
Communication Standard
While exposure and risk assessment 
continues, OSHA needs to implement the 
new Hazard Communication standards and 
enforce accurate risk communication and 
warning labels for BPA through retooled 
material safety data sheets (MSDS).
Manage BPA Risks Using the  
General Duty Clause and Establishing 
Permissible Exposure Limits
As more risk assessment and exposure  
data come in, OSHA needs to establish  
a Permissible Exposure Limit for BPA.  
OSHA should also consider utilizing such 
data to regulate BPA under the General 
Duty Clause.  
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Protecting the Public from BPA:
Introduction
The mounting body of scientific research concerning BPA has provided a solid base of 
information upon which federal agencies can build public safeguards.  What we now know 
about BPA is ample basis for concern about its safety, and in preparing this paper and the 
regulatory options we recommend, we have paid careful attention to the current state of that 
research.  Just as important, what we do not yet know about BPA 
is significant, and those remaining questions provide the basis for 
recommendations contained in this report.  We need to establish 
a more complete knowledge base of exposure levels through 
individual pathways (i.e., food, water, air, consumer products, 
and soil contamination).  We also need to know more about 
cumulative levels of exposure and how the timing and route 
of exposure impacts metabolism of the chemical.  Filling these 
knowledge gaps is an important component of understanding 
BPA and how best to protect the public from its health risks.  
As scientists and regulators gather this information, however, 
they need not wait to implement certain safeguards against the 
demonstrated health risks of this endocrine-disrupting chemical.
BPA Uses
 ■ Plastic food and beverage containers
 ■ Plastic eating utensils
 ■ Baby bottles & sippy cups
 ■ Reusable water bottles
 ■ Canned foods and beverages (including 
infant formula)
 ■ Kitchen appliances
 ■ CDs & DVDs
 ■ Dental sealant
 ■ Medical devices
 ■ Epoxy linings (used on everything from 
tin cans to jar lids to soda cans)
 ■ Thermal paper (i.e. store receipts)
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The Current State of BPA
The Known Risks of BPA and Inadequate Regulatory Safeguards
Without credible government regulation of perceived risks, alert consumers sometimes  
find ways to protect themselves from perceived risks through marketplace pressures.   
The grassroots movement to ban BPA from such popular items as baby bottles and 
reusable food containers is a prime example.  “BPA-Free” labels abound where just a few 
years ago most people, including mothers, were unaware of the chemical or its dangerous 
effects.  Individual companies, such as Nalgene, have voluntarily 
eliminated the chemical from their products. Walmart instituted 
procurement and sales policies aimed at eliminating BPA 
from baby bottles. While these measures have helped to spur 
government action and bring BPA into the consumer spotlight, 
they do not go far enough to impose broad-spectrum protections 
for the unaware public or for the individuals who struggle to pay 
premium prices for “kid-safe” products.  
An example of the lack of broad-spectrum protection is that 
grassroots-induced regulation and marketplace pressures do not 
prevent companies from substituting one dangerous chemical 
for another.  In the case of BPA, some manufacturers of products 
labeled “BPA-Free” merely replace BPA with its close chemical 
cousin Bisphenol-S (BPS), which has also demonstrated estrogenic 
activity and potential endocrine-disrupting effects in recent 
testing.12  Additionally, the narrow, if understandable, focus on 
BPA in baby products ignores that children are also exposed to 
BPA in their toddler years, through BPA’s use in food cans, for 
example.  Federal regulation by agencies like FDA, EPA, and 
OSHA is a more comprehensive solution, one that can offer 
universal safety standards and guidance to spur innovative and safe 
solutions, while removing obvious risks to consumers.  Federal 
regulation can also ensure that the information concerning BPA’s 
known risks and presence in consumer products is being provided 
to consumers in an accurate, consistent, and meaningful manner.
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Protecting the Public from BPA:
A Snapshot of Existing International, State, and Local BPA 
Controls
BPA is subject to a range of international, state, and local controls aimed at the chemical’s use 
in baby products, primarily bottles, sippy cups, and some reusable beverage containers. 
Jurisdiction Date Passed Type of Regulation Effective Date
Cities
Chicago, IL May 13, 
2009
Ban on the sale of baby bottles and sippy cups 
containing BPA.
January 31, 2010
Washington, 
D.C.
January 
12, 2011
Prohibits BPA in reusable food or beverage 
containers meant for children four and 
younger.
July 1, 2011
States
California August 
30, 2011
Statewide ban of selling and/or making baby 
bottles and sippy cups containing BPA.
July 1, 2013
Connecticut June 4, 
2009
Prohibits BPA in infant formula packaging, 
baby food cans and jars, and reusable food 
and beverage containers.
October 1, 2011
Delaware June 30, 
2011
Prohibits the sale or offering for sale of bottle, 
sippy cup, or other food contact container 
intended for use by children up to the age of 
four.
Immediately 
effective against 
manufacturers.
January 1, 2012 -  
Retailer ban 
effective.
Maine April 12, 
2011
Prohibits BPA in reusable food and beverage 
containers.
January 1, 2012
Maryland April 13, 
2010
Prohibits BPA in children’s products. January 1, 2012
Massachusetts December 
15, 2010
Prohibits BPA use in reusable food and 
beverage containers for children three and 
younger.
January 1, 2011 – 
Manufacturer ban 
effective.
July 1, 2011 
– Retailer ban 
effective.
Minnesota May 8, 
2009
Bans BPA in sippy cups and baby bottles. January 1, 2011
New York July 31, 
2010
Bans the sale of baby bottles and other 
children’s products containing BPA.
December 1, 2010
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States
Vermont May 20, 
2010
Ban of BPA in baby bottles, sippy cups, 
reusable food and beverage containers, and 
infant formula cans.
July 1, 2012
July 1, 2014 (metal 
cans)
Washington 2008 
May 19, 
2010
Manufacturers of children’s products must 
report use of “chemicals of concern” 
(including BPA).
Ban of BPA in baby bottles and sippy cups  
for products intended for children under  
3 years of age.
Ban of BPA in sports bottles.
August 2010 
 
July 1, 2011 
 
July 1, 2012
Wisconsin March 3, 
2010
Ban of BPA in cups and bottles intended for 
children 3 and younger.
June 2010
Countries / International Authorities
Canada April 2008
October 
2010
Ban of sale of baby bottles with BPA.
BPA declared a toxic chemical.
March 31, 2010.
Effective upon 
declaration.
Japan Between 
1998 and 
2003
Voluntary industry-wide replacement of BPA 
epoxy linings in soda and tin cans.
Voluntary replacement of school tableware.
N/A
China May 30, 
2011
Joint notice from health ministries banning 
BPA use in production and sale of baby 
bottles.
Production 
prohibition – June 
1, 2011
Malaysia March 14, 
2011
Ministry of Health announced ban of BPA in 
polycarbonate baby bottles.
March 1, 2012
European 
Union
N/A Ban on manufacturing baby bottles with BPA.
Ban of sale and marketing of baby bottles  
with BPA.
March 1, 2011
June 1, 2011
France June 2010 Joint notice from health ministries banning 
BPA use in production and sale of baby 
bottles.
Production 
prohibition – June 
1, 2011
Denmark March 
2010
Temporary ban on BPA use in all food contact 
materials intended for use by children  
under three.
July 1, 2010
These initiatives (with the exception of Japan’s voluntary initiative) leave unaddressed other 
major uses of BPA, such as epoxy linings and other common food containers or utensils, 
leaving a large gap in health and safety protections.
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Protecting the Public from BPA:
Meager Efforts at the Federal Level
Troubled by the inaction of federal agencies charged with responsibility for regulating toxic 
endocrine disrupters, in late 2010, Sen. Diane Feinstein sponsored an amendment to the 
Food Safety Modernization Act that would have banned BPA from baby bottles, sippy cups, 
and materials used in infant food and formula cans; however, in last-minute negotiations, 
the amendment was dropped.  Unfortunately, no efforts to regulate BPA through federal 
legislation have resurfaced.
Most of the statutory regimes under which the federal agencies operate require intensive risk 
assessment prior to moving forward with any risk management regulations.13  Fully assessing 
BPA’s risks has been a complicated endeavor because the protocols that federal agencies have 
established over the years were designed to investigate chemicals that impact human health in 
relatively straightforward ways.  “The dose makes the poison” is the way toxicologists describe 
how most chemicals interact with our bodies.  But BPA is different.  Researchers have found 
“nonmonotonic dose response functions” (adverse effects at both low-dose and high-dose 
ends of the spectrum) when they have exposed pituitary, prostate cancer, and other cells to 
BPA.14 Despite these testing protocol struggles, scientists have made progress in identifying 
BPA’s hazards and dose-response relationships but more information is needed concerning 
low-dose exposure and non-acute adverse effects.  Accordingly, federal agencies have taken 
a more cautious approach than state legislatures in the BPA battle by focusing on revisiting 
toxicological risk assessments and funding additional exposure studies.
Beginning in 2008, the National Toxicology Program’s Center for Evaluation of Risks 
to Human Reproduction (NTP-CERHR) released a report, which concluded that some 
concern existed about infants’ and children’s exposure to BPA.15  Nevertheless, right on 
the heels of this report, FDA released its own findings that an adequate margin of safety 
remained for BPA’s use in food contact sources.16  Two years later, in 2010, FDA changed its 
position in a new report, titled “Update on Bisphenol A for Use in Food Contact Applications,” 
and adopted (with some caveats) the position of NTP-CERHR that it shared some concern 
“about the potential effects of BPA on the brain, behavior, and prostate gland of fetuses, 
infants and children.”17  FDA emphasized that despite its change in position, “substantial 
uncertainties” existed concerning the scientific studies and recommended that future efforts 
focus on clarifying these scientific uncertainties.18  As data mounts, FDA is expressing more 
and more concern about our exposure to BPA through food and announced its support 
for “a shift to a more robust regulatory framework for oversight of BPA.”19  Despite these 
intentions, the regulatory tools available to the agency are difficult to muster for reasons we 
explain below, and little progress has been made.
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The Environmental Protection Agency (EPA) has made a few more tangible steps toward 
regulating BPA.  In March 2010, EPA issued a BPA Action Plan outlining its intentions to 
increase scientific evaluation of BPA, monitor, and analyze environmental exposure pathways 
and risks, and, depending on the research findings, potentially issue new regulations under 
the Toxic Substances Control Act (TSCA).20  The BPA Action Plan noted that the agency 
will defer to FDA and the National Institute of Environmental Health Sciences (NIEHS) 
for all human-related risk or exposure analysis of BPA—a position encouraged by the White 
House.21  EPA proposed new testing requirements that would solidify the knowledge base 
about BPA’s impacts on plants, animals, aquatic life, and environmental accumulation.22   
The agency also may include BPA in a first-of-its-kind “Chemicals of Concern List.”23
Combined, these efforts from the federal agencies show promise but do little for the public 
in the near future to provide tangible safeguards or, at the very least, meaningful consumer 
information.  Furthermore, the proposed regulatory efforts do little to clear a path for more 
stringent and long-term regulatory options.  With this basic lay of the land in mind, we now 
turn to each of the three agencies individually to examine what tools they might use now and 
what tools might become available to them as the science develops. 
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Protecting the Public from BPA:
Short Term & Long Term  
BPA Regulatory Options
Food and Drug Administration
The majority of human exposure to BPA comes through consuming food and beverages.  
It can be found in a variety of the containers used to store, process, and serve food and 
beverages, making the chemical a significant public health concern.  From reusable water 
bottles, to baby bottles, to plastic utensils, to linings on soda cans, infant formula cans, 
 and tin cans, BPA comes into contact with the food and beverages of a large swath  
of the population.  One study specifically designed to represent an accurate cross-section  
of the U.S. population showed BPA’s presence in the urine of 95 percent of adults  
who participated in the Centers for Disease Control screening program.24
Through BPA’s use in food packaging and containers (or “food contact materials”), the 
chemical can leach into the food or beverage becoming what is known to FDA as an 
“indirect food additive” or a “food contact substance.”25  Despite FDA’s clear authority 
to regulate BPA’s presence in the American food supply, BPA occupies a space in FDA’s 
regulatory landscape that is complicated by a number of overlapping legal mandates, 
regulations, exemptions, and loopholes.
A Complex Regulatory Landscape
FDA first obtained authority to regulate food additives in 1958 and the half-century saga  
of subsequent regulatory efforts is not a success story from a public health policy perspective.  
The theory behind the regulatory system was sound – if a company wanted to use a chemical 
in food packaging, it had to petition FDA for a premarket clearance determination that  
the use was safe.  Unfortunately, the system has failed in practice.
To begin, Congress passed a law which had two major loopholes:  (1) if the use of a chemical 
was already sanctioned by FDA prior to 1958, a petition wasn’t necessary; and (2) if qualified 
experts would generally recognize the use of a chemical as safe, a petition wasn’t necessary.  
Industry exploited the first loophole by reading pre-1958 sanctions broadly.  It exploited the 
second loophole by funding enough research on diet and toxicology that, over time, industry 
and FDA reached something of a stalemate and industry stopped petitioning FDA for safety 
determinations if a chemical cleared certain toxicological assays or simply could be calculated 
to migrate into food at low levels.26  
Through litigation and administrative advocacy, industry opened other loopholes in the 
law.27  Under the “housewares exemption” to the petition process, industry presumes that a 
petition is not necessary if the end-use of a chemical will be a “houseware” item like paper 
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cups or plates, plastic utensils, or cooking utensils.  Further, under a policy on mixtures of 
already-approved substances, industry will not submit a petition if all of the components of a 
new food packaging material have been individually approved and the new use fits within the 
already-approved conditions of use.  And under the “basic resin” (or “basic polymer”) policy, 
industry does not submit petitions for the various chemicals used as catalysts, reactants, or 
other agents in the complex process of creating resins (assuming the chemical is used in small 
quantities and isn’t subject to other regulatory provisions).  As a result, while some BPA uses 
in food contact materials went through the approval process, these loopholes have likely been 
exploited for many other uses of BPA, raising concerns about FDA’s basic knowledge about 
exposure routes and the underlying human health hazards of BPA.
Congress attempted to repair the system when 
it amended the FDCA in 1997.  As part of the 
amendments, Congress created the Food Contact 
Substance Notification system.28  It didn’t replace 
the petition process—a company can still petition 
FDA for a premarket determination that the use of 
a particular substance is safe—but it did attempt to 
streamline some of the administrative procedures.  
Under the new notification system, companies 
simply inform FDA that they had made their own 
determination that a new use of a substance for 
food packaging was safe under certain conditions.  
If FDA doesn’t respond to the notification in 
120 days, the use of the substance as described 
in the notification is considered to be sanctioned 
by FDA (or, in FDA parlance, the notification 
is “effective”).29  As a backstop against dangerous 
substances slipping into the market because of 
the short timeframe for FDA review in this new 
process, FDA can request that a manufacturer submit a petition under the old process when 
FDA feels reviewing a petition is “necessary to provide adequate assurance of safety.”30
The overlapping regulatory schemes created by the notification process and petition process, 
along with the various loopholes that could be utilized, create a complicated landscape for 
promulgating new safety standards on BPA.  Further confounding matters, the scientific 
evidence regarding BPA’s health hazards and the range of exposure scenarios faced by 
the public continues to evolve.  Nevertheless, FDA has the option of taking several key 
regulatory actions that could promote public confidence and safety.
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Protecting the Public from BPA:
Expanding Data-Gathering Requirements 
New information about BPA’s health hazards and toxicological modes-of-action seems to 
be hitting the scientific literature on a daily basis, yet more is needed to implement any 
new food packaging safeguards.  Not only does FDA need more information on real-life 
exposures, how BPA is used, and how much of it we’re ingesting, but the agency also needs to 
revisit some of its fundamental risk assessment protocols and policies that instruct any health 
hazard data collection efforts.  FDA has several different regulatory tools that it can use to 
expand its data-gathering capacity and implement stricter use standards, each with relative 
strengths and weaknesses.
The agency should pursue its plan to perform both independent and collaborative 
research projects to assess newly identified health risks and exposures.  In FDA’s January 
2010 BPA Update Report, the agency affirmed its commitment to both its own independent 
research efforts and inter-agency research efforts focused on investigating BPAs low-dose 
endocrine-disrupting effects.  FDA cited three collaborative projects between the National 
Center for Toxicological Research and National Toxicology Program, as well as a $30 million 
fund from the National Institute of Environmental Health Sciences (a portion of which 
would go to FDA) to conduct further independent or collaborative research projects.31  
These risk assessment efforts are critical and FDA must continue to be assertive in its  
pursuit of collecting additional toxicity and exposure data on BPA through both  
independent and collaborative research efforts.  Understanding that these research projects 
take time to complete, starting these research projects and continuing with those already 
moving forward must be a paramount short-term goal undeterred by reduced agency 
budgets, industry bullying, and political pressures.  Results from this research will bridge  
the gap between the more recent scientific studies demonstrating low-dose adverse effects  
of BPA and the outdated scientific research underlying the ineffective food contact substances 
guidance and regulations.
Sharpening FDA’s New Food Safety Tool
With the passage of the Food Safety Modernization Act in 2009, Congress at 
long last granted FDA mandatory recall authority.  While this recall authority 
was granted to more effectively deal with acute outbreaks of food-borne 
illnesses, such as salmonella and e. coli, FDA should consider using this new 
food safety tool to recall certain foods containing toxins such as BPA, if 
health hazard concerns become too great and traditional regulatory methods 
ineffective at protecting the public.
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As another short-term option, the agency should also use its authority under the Food 
Contact Substance Notification program to collect more specific toxicity and exposure 
data from BPA manufacturers and processors.  FDA need not shoulder the entire burden 
of implementing new testing procedures and culling BPA toxicity and exposure data.  
Instead, FDA can issue new guidance recommending that any company that applies for 
a new BPA use through the Food Contact Substance Notification process must provide 
toxicity, safety, and exposure data as a part of its submission.  These data should include risk 
and exposure data beyond that which is already required and/or recommended.32  To obtain 
these data, the manufacturer or processor would mostly likely need to conduct experiments 
using dose levels below those traditionally thought to be “safe,” expand the definition of 
adverse effects to include more subtle endocrine-disrupting effects, and expand the scope  
and diversity of study endpoints (i.e. the symptoms, disease, behavior, etc. that a study 
aims to determine).33  These changes in testing protocols would require testing beyond that 
which is specifically outlined in the official FDA food safety assessment manual called the 
Toxicological Principles for the Safety Assessment of Food Ingredients, more commonly known  
as the Redbook.34
For example, Food Contact Substance Notifications must include a Comprehensive 
Toxicology Profile (CTP) in support of an applicant’s “safety summary,” which is simply 
the applicant’s assertion of a food contact substance’s safety as used in the specific manner 
described in the notification application.35  The CTP should include  “summaries of all the 
available toxicological information pertinent to the safety evaluation of the [food contact 
substance].”36  Beyond these submission requirements, FDA also asks its Food Contact 
Substance Notification applicants to perform certain safety studies, as determined by the 
food contact substance’s “cumulative estimated daily intake” (CEDI).  The CEDI is often 
based on the “no observed adverse effect level” (NOAEL), which is the highest dose of a 
substance that does not show adverse effects.37  Thus all the safety data submitted for a  
Food Contact Substance Notification application rest on the traditional “dose makes the 
poison” risk assessment philosophy and often focus on assessing only overt adverse effects  
like severe birth defects or tumors.38  Again, in the case of BPA (and other endocrine 
disruptors) this traditional approach to safety assessment fails to identify some of the key 
health hazards that recent scientific studies operating outside of the traditional Redbook 
protocols have identified.
To remedy this risk assessment disconnect, ideally, FDA needs to rewrite its Redbook 
protocols for endocrine disruptor testing, but this would require a lengthy scientific and 
administrative process, pushing this solution into the long-term category and requiring a 
look at more than just BPA.  As an alternate short-term option, FDA can issue new BPA 
Food Contact Substance Notification guidance that redefines not only the parameters for 
which existing studies should be summarized and included in the CTP, but also expands the 
range of safety studies that a Food Contact Substance Notification applicant should conduct 
as a part of its submission for a new BPA use.  
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Establishing Stricter Use Standards
FDA could also develop new Food Contact Substance Notification guidance that 
establishes stricter and more precautionary new use standards.  When a BPA 
manufacturer or processor submits a Food Contact Substance Notification application, 
they are requesting approval for a specific use.  Accordingly, FDA expects that once a Food 
Contact Substance Notification is approved, the holder of the effective Food Contact 
Substance Notification will operate within the use limitations.  These use limitations include 
maximum concentrations of particular chemicals in a food contact material, restrictions on 
the types of food that should be packaged in the material, and limitations on temperatures 
and durations of food contact.39  To better protect consumers from BPA hazards, FDA should 
establish through guidance a new set of stricter use conditions for potential Food Contact 
Substance Notification applicants.  This guidance should announce that any proposed new 
BPA use involving contact with certain types of food (e.g. infant formula) or distribution to 
certain companies (e.g. baby bottle manufacturers) is unsafe and will reslt in a denial letter.40  
To extend these data collection and stricter use 
standards to existing Food Contact Substance 
Notifications, FDA would need to revoke existing 
notifications and require reapplication under the 
new guidance and safety standards.  Reforming the 
Food Contact Substance Notification guidance and 
underlying policies is only a first step toward improving 
our understanding of food-contact risks posed by 
BPA, because these data collection requirements and 
stricter use standards would only apply to a small and 
somewhat insignificant portion of the food contact 
material market—previously unapproved uses.  Once 
a notification is approved, really the only way for FDA 
to impose new data collection requirements and use 
standards is to revoke the notification, thus requiring 
a resubmission.  FDA rarely invokes this revocation 
authority.  For this reason (and for the potential litigation 
that might follow any revocations) this regulatory option 
is considered longer-term. While these actions would 
be new territory for FDA in utilizing the notification 
process, it is a territory worth exploring.
Voluntary Food Contact Substance 
Notification Submissions
In its BPA Update Report, FDA announced an 
intention to extend potential BPA testing and data 
collection requirements to BPA manufacturers and 
processors holding already-approved Food Contact 
Substance Notifications, through a voluntary 
program.   Because voluntary programs lack any 
threat of sanctions, the obvious problem with this 
approach is that companies that would have no 
obligation to notify FDA of their BPA use are unlikely 
to voluntarily invest time, money, and effort into 
compiling a Food Contact Substance Notification 
submission just because FDA would like them to.  
Without some incentive to comply (e.g. potential 
fines or revocation), it is doubtful that this voluntary 
method would lead to any significant strides in BPA 
regulation or monitoring.
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Consumers’ Right-to-Know
FDA has the ability to empower people to act in their role as consumers and further motivate 
industry behavior through implementing new BPA labeling guidance and regulatory 
standards.  Progressive consumerism, or “regulation via internet,” often achieves results 
where traditional legislative and regulatory methods lag or run into administrative hurdles.  
Progressive consumerism is not a full solution because the outcome often lacks coherent 
results on which consumers can rely, but it is a partial solution and one that has proven 
successful in altering BPA usage and consumer awareness.  Through labeling guidance and 
regulation, FDA can provide consumers with more information and safety assurances and 
take any existing BPA regulation to the next level.
A short-term option for establishing labeling 
standards would be to issue guidance 
concerning the use of “BPA-Free” labels.  
This guidance should establish basic safety 
standards for the use of the “BPA-Free” label 
and ban the use of such a label if the food 
contact material used in a product contains 
a BPA substitute that has demonstrated any 
similar endocrine disrupting effects. One 
example of such labeling guidance is the 
document in which FDA offered detailed 
advice on the “appropriate labeling statements” 
for milk products claiming to be “rbST free.” 41  
This guidance demonstrates FDA’s ability and 
willingness to regulate industry-created labels 
aimed at cashing in on consumer concerns 
about potentially unhealthy chemicals.
The “BPA-Free” guidance should outline specific criteria that FDA deems proper use of the 
“BPA-free” label.  For example, the manufacturer, producer, or distributer wishing to use the 
“BPA-free” label must submit a list of food contact materials included in its product, identify 
if BPA previously existed in the food contact material, and, if so, what substitutes took the 
place of BPA.  Additionally if a substitute for BPA was utilized, the manufacturer, producer, 
or distributer should be prohibited from labeling its product “BPA-free” if the substitute 
exhibits any endocrine-disrupting or estrogenic qualities. This labeling guidance could apply 
to both existing notifications and new use applications.
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FDA should issue BPA labeling regulations setting forth 
mandatory BPA identification requirements, substitution 
standards, and “BPA-Free” usage standards.  Consumers 
have a right to know what toxins are in their food, whether that 
toxin’s presence enters the food supply directly or indirectly.  
In BPA’s case, FDA can acknowledge this right-to-know by 
issuing a regulation that establishes mandatory BPA labeling 
standards and disclosure requirements for any food contact 
material containing BPA.  To issue such a regulation, however, 
would indeed be a long-term option because of the complex 
and often drawn-out rulemaking procedures that accompany 
the promulgation of a regulation.  The long-term nature of 
such rulemaking, however, has not stopped FDA from issuing 
mandatory labeling regulations before.42  Ideally BPA labeling 
standards would take the form of a regulation that sets specific labeling and substitution 
requirements and applies to all BPA food-contact uses, manufacturers, and distributors.
FDA’s Long-Awaited Response to the Natural Resources Defense 
Council Petition
In 2008, the Natural Resources Defense Council (NRDC) filed a petition much like 
that of the ACC requesting that FDA promulgate a new regulation concerning 
BPA’s use in food contact substances.  Of course, there were two major difference 
between the two requests:  First, unlike the ACC’s petition requesting a mere 
amendment to existing regulations to ban the very specific use of BPA in baby 
bottles and sippy cups, the NRDC petition requested that FDA promulgate a new 
regulation prohibiting all uses of BPA in all food contact substances.  Second,  
the NRDC asked that FDA issue this ban based on a finding that BPA is unsafe  
to human health.  The NRDC received no response from FDA and was forced  
to file a complaint in the Southern District of New York to compel agency action.  
On December 7, 2011, FDA and NRDC reached a settlement and a Consent Decree 
was filed with the court, setting March 31, 2012 as the deadline for FDA to make  
a final and reviewable agency decision on the NRDC petition. 
BPA Labeling in France
In September, France’s ecology minister 
announced that the French version of the FDA, 
the Agency for Food Health Safety, would seek 
systematic and mandatory labeling of BPA-
laden food packaging products that come 
into contact with the public.  Not stopping 
there, the minister also intended to ban BPA 
use in specific products where a proven safer 
substitute existed.
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A Recommendation of What Not to Do: 
In September, the American Chemistry 
Council, a staunch defender of unfettered 
BPA use, caused a stir amongst anti-BPA 
advocates by filing a petition with FDA that 
requested an amendment of an existing BPA 
regulation that designated BPA’s use in baby 
bottle and sippy cups as safe.  Shockingly, 
the ACC requested that these specific uses be 
removed from the “safe use” category because 
BPA manufacturers had stopped using BPA 
for these products.  Issuing a new regulation 
that fails to identify the true reasons for BPA 
regulation—health hazards—is not an effective 
use of energy, time or resources.
Implementing Universal Safeguards Against Dangerous Uses of BPA 
To address the full spectrum of BPA uses and establish the most meaningful regulatory 
safeguards against unsafe uses, FDA should implement new, health-based BPA 
regulations.  Taking its regulatory authority one step further than testing and labeling 
requirements and using both the existing risk assessment data and data arising from on-
going scientific studies, FDA needs to promulgate new regulations and corresponding 
guidance that account for BPA’s (and its substitutes’) low-dose endocrine-disrupting effects.  
For a starting point, the scope of these rules should restrict BPA’s uses in food contact 
materials targeted for use in the sensitive populations of pregnant women, infants, and 
children, because the mounting scientific data indicate these are the populations most at risk 
to suffer from BPA’s low-dose endocrine disrupting effects and achieving scientific data on 
these populations is challenging.  
As a long-term option, FDA should issue new regulations 
concerning all BPA uses, regardless of loopholes and previous 
approvals.  Whether FDA approved the use of a substance 
through the petition process or the notification process, or 
the use falls under one of the many statutory exemptions and 
loopholes, the agency retains the discretion to consider new 
regulations for any additive if the Commissioner determines 
that the use is unsafe and existing regulations do not adequately 
protect the public health.  “If new evidence suggests that a 
product already in use may be unsafe, or if consumption levels 
have changed enough to require another look, federal authorities 
may prohibit its use or conduct further studies to determine if 
the use can still be considered safe.”43  Although time-consuming 
and certain to be faced with industry challenges, FDA thus has 
the power to issue new regulations concerning any use of BPA 
in a food contact material.  FDA should use this authority to 
impose a range of potential safeguards, from banning BPA in 
all food contact substances to banning particular uses (e.g. baby 
bottles) to requiring new risk assessment and monitoring data 
submissions for all manufacturers or processors of BPA.
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Environmental Protection Agency 
Limiting exposure to BPA through food is an important regulatory goal, but it would affect  
a very small portion of the total BPA production output.  Consider:
Chemical companies and trade groups aren’t willing to divulge numbers, but market 
analyst reports estimate global annual BPA demand at up to 12 billion [pounds]  
and growing at 5 percent per year.  Polycarbonate makes up 74 percent of BPA use, 
and epoxy resins consume about 20 percent of production.  But the baby bottle  
and food-can applications combined accounted for less than 5 percent of BPA  
consumption.  That means the [grassroots-spurred] phaseouts haven’t put a big dent  
in overall BPA use.44 
In other words, to address all the risks posed by BPA, regulation must also focus on the 
myriad sources of BPA in our lives that FDA cannot address.  This is a job for EPA, whose 
authority is broader than food packaging and thus can reach up the supply chain to the 
manufacturers of the raw material.45
According to EPA’s Toxics Release Inventory, companies that manufacture and use  
BPA release the chemical into the air, water, and soil in quantities exceeding 1 million 
pounds per year.46 EPA has even identified BPA’s potential effects on aquatic species as an 
area of concern.47  The agency has a number of statutes at its disposal that could be utilized 
to manage BPA risks, including the Safe Drinking Water Act (SDWA), Clean Air Act (CAA), 
Clean Water Act (CWA), and Resource Conservation and Recovery Act (RCRA).  But  
before the agency can use the tools available under those statutes, it must first develop  
a fuller risk assessment, combining what is already known about BPA’s hazards with  
up-to-date information on the human and environmental exposures that could be  
regulated under each law.  
BPA’s IRIS Profile
EPA maintains a database, called the Integrated Risk Information System (IRIS), that 
contains toxicological profiles on hundreds of industrial chemicals.  Updating the IRIS 
profile for BPA to reflect current hazard and dose-response information should be an 
immediate priority.  The existing profile is woefully out-of-date (July 1993 is the most recent 
revision listed) and it is lacking in meaningful information.  Where other chemicals have 
“inhalation reference concentrations” that indicate conservative levels of concern for various 
adverse health effects caused by chemicals found in the air, BPA’s IRIS profile has “no data.”48  
Where other chemicals have quantitative estimates cancer risks, BPA’s IRIS profile has “no 
data.”  The one datapoint that can be found in the BPA profile is an oral reference dose—but 
the “critical effect” that undergirds that number is reduction in body weight, as opposed to a 
health effect that is more relevant to the state of current knowledge about BPA’s hazards, like 
impacts on the endocrine and reproductive systems.
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As a short-term option to address BPA, EPA should update BPA’s IRIS entry to include 
current data to reflect the risks that have recently come to light, especially concerning 
low-dose effects.  As part of the update process, EPA should develop generic guidance 
for hazard identification and dose-response assessment of endocrine-disrupting chemicals, 
using BPA as a test case.  The agency already has generic guidance for various principles 
of risk assessment, like exposure assessment or determination of reference doses that focus 
on carcinogenicity and other adverse health outcomes.  It does not have guidance specific 
to endocrine disruptors.  EPA also has generic guidance documents related to assessing 
risks for certain classes of chemicals, like metals or dioxins.  Building off of these existing 
guidance documents and policies, the agency should develop guidance for assessing risks 
posed by endocrine disruptors.  The process of developing that guidance would enable EPA 
to simultaneously update its IRIS profile for BPA to reflect the newest research on its hazards.
TSCA Regulatory Options
Congress passed the Toxic Substances Control Act (TSCA) in 1976 as a gap-filling 
measure, because the major air pollution, water pollution, and waste disposal statutes 
failed to fully address the problem of human and environmental exposure to potentially 
dangerous chemicals in productive use.  TSCA has two main environmental objectives.  
First, TSCA was intended to protect humans and the environment from risks posed by 
industrial chemicals and other substances.  Second, the drafters of TSCA were prescient in 
understanding that lack of environmental and health information (the “data gap”) would 
present the biggest hurdle for regulation of industrial chemicals, and so TSCA also contains 
several provisions to require the manufacturers of covered chemicals to generate and report 
such data to EPA.  TSCA’s  short-comings have prompted environmental advocates to 
press for new, replacement legislation, but the current statute nevertheless provides EPA 
with several options to improve exposure and use information about BPA through testing 
requirements and manage the chemical’s risks through regulation.
(1)  BPA Test Rule
The first short-term option available to EPA is for it to continue its progress toward 
issuing a BPA Test Rule under TSCA§ 4.  This section of TSCA allows EPA to promulgate 
rules requiring manufacturers to shoulder the responsibility for exposure and risk assessment 
testing of chemicals that EPA finds may present an unreasonable risk of injury to health or 
the environment and/or are present in the environment in such quantities that they present 
a significant exposure risks to either the environment or humans.49  These findings are 
commonly referred to as a “hazard” or “A” finding (the “A” referring to subsection A of § 4) 
or an “exposure” or “B” finding.50  One or both of these findings must be made in addition 
to a showing that existing data are inadequate for risk assessment and that the proposed 
testing is necessary to develop the data.51  EPA rarely imposes test rules on manufacturers 
of chemicals that were already in commerce when TSCA was created,52 but seems willing to 
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make one of its rare exceptions in the case of BPA because new exposure pathways and new 
information about low-dose effects are only recently coming to light.53
EPA initiated the § 4 rulemaking process for BPA in October 2010 and sent a draft Advance 
Notice of Proposed Rulemaking (ANPRM) to the Office of Information and Regulatory 
Affairs (OIRA) at the White House for review in December 2010.  Although EPA hoped to 
publish the ANPRM by March of 2011 (and, by Executive Order, OIRA had only 10 days 
to review the ANPRM), the edited announcement was not published in the Federal Register 
until July 2011.54  Delayed but still holding true to EPA’s intended purpose, the published 
document proposes requirements for sampling and monitoring of surface water, ground 
water, drinking water, soil, sediment, sludge, and landfill leachate in the vicinity of expected 
BPA releases.  These testing requirements are designed to aid EPA in determining whether 
potentially sensitive organisms may currently be exposed to concentrations of BPA in the 
environment that are at levels of concern for adverse effects.55  None of the proposed testing 
in the BPA Test Rule would focus on human health effects or exposure analysis, a focus 
seemingly driven by administrative and industry pressures based on the Office of Information 
and Regulatory Affair’s edits to EPA’s Advanced Notice of Proposed Rulemaking for the 
proposed BPA Test Rule released this past summer.56
EPA’s intentions to address only environmental exposure and risks (and to specifically 
exclude human health effects) squanders an opportunity to collect valuable information.  
EPA’s authority to protect human health is separate and distinct from FDA’s.  Should FDA 
take no action to regulate BPA or ensure proper labeling, EPA would have that authority 
under TSCA, but the agency hamstrings itself by not including human health effects in its 
proposed test rule.  Moreover, TSCA gives EPA jurisdiction over the many manufacturers 
and commercial users of BPA who profit from the 95 percent of the chemical that does not 
go into baby bottles and sippy cups.  The information that these companies already possess 
(or could develop if prompted by a § 4 test rule) could significantly enhance our knowledge 
about exposure scenarios that EPA might regulate using its powers under the CWA, CAA, 
RCRA, or another statute.  Because of the time it takes to develop the testing requirements, 
promulgate a final rule, compile the test rule data, and then analyze this data, EPA must act 
expediently and finalize the BPA Test Rule.
(2) TSCA § 5(b)(4):  Chemicals of Concern
Another short-term option available to EPA is to list BPA on its “chemicals of concern” 
list to further educate the public about the chemical’s risks.  EPA has indicated a 
willingness to include BPA in a sort of “regulatory watch” under TSCA § 5(b)(4), which gives 
the agency the authority to “compile and keep current a list of chemical substances … which 
the Administrator finds … presents or may present an unreasonable risk of injury to health 
or the environment.”57  The § 5(b)(4) list is otherwise known as the “chemicals of concern 
list.”  From a regulatory standpoint, the effect of adding a chemical to the list is limited to 
“soft” regulation that does not impose any restrictions on a chemical’s manufacture or use.  
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Once listed, loopholes for small manufacturers and importers of the chemical cinch up, 
forcing them to periodically provide EPA with data on production volumes and downstream 
uses; significant new use notifications related to the chemical must include data showing 
that the new use will not present an unreasonable risk; and certain export notification rules 
will apply.58  The real power of the list lies in its potential to begin reducing toxic ignorance.  
Government has a duty to inform the public about toxic risks that they may not recognize, 
and to do so in a way that empowers the public to act (make wise purchasing decisions, 
engage in government decision-making).  Listing could also impact the supply chain, 
prompting downstream firms to demand feedstock or components that are free of substances 
found on the chemicals of concern list.  BPA presents widespread concerns across many 
federal agencies’ jurisdictions, so it is an ideal chemical for inclusion on EPA’s chemicals  
of concern list.
To date, EPA has not utilized its 5(b)(4) authority—a fact most likely due to the threat of 
litigation.  Citing judicial precedent from other EPA applications of TSCA controls, the 
U.S. Chamber of Commerce and others who oppose EPA’s use of this regulatory tool argue 
that to place a chemical on the 5(b)(4) concern list, EPA must produce a substantial risk 
analysis before listing the chemical.59  Given that the statutory text states that EPA need 
only demonstrate that a chemical of concern “may present unreasonable risk” and thus sets 
a standard lower than that required for stricter regulation under other TSCA sections, it 
does not follow that Congress envisioned this list to impose a regulatory burden equal to its 
more stringent counterparts.  Logically, the chemicals of concern list is one of the middle 
steps between unfettered use of a chemical and full on regulatory bans or use restrictions.  
Establishing significant hazards and widespread use should be enough to list a chemical that 
we need to know more about.
EPA should proceed with plans to compile the list and its intention to include BPA on 
it.60  The agency has created a draft rule that would for the first time establish a chemicals of 
concern list (including BPA), but that rule has been under review by OIRA since May 12, 
2010.61  OIRA’s exceptionally slow review has prevented EPA from taking the smallest step 
toward promulgation of the list—proposing it in the Federal Register and collecting public 
comment on the proposal.  This goes against principles of good government by forestalling 
broad public engagement but encouraging moneyed interests to dominate the debate.  
Extracting a stalled rule from OIRA’s review process is a difficult political task for EPA 
officials given OIRA’s role as the White House enforcer on regulatory priorities; however, the 
chemicals of concern list has the potential to enhance EPA’s entire toxics program by creating 
a new avenue for communicating with the public, chemical manufacturers, and the entire 
supply chain about potential toxic hazards.  
Labeling and Other Regulatory Options Under TSCA § 6
Building on the known risks of BPA and the additional scientific data collected through 
the short-term regulatory options described above, EPA should utilize TSCA § 6 and 
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move forward in a long-term effort to develop more stringent and comprehensive 
regulations such as warning labels, specific use restrictions, and even bans on specific 
uses.  In § 6, Congress granted EPA broad authority to regulate the manufacture, processing, 
distribution, use, and disposal of a chemical substance using a wide variety of regulatory 
tools, ranging from labels to outright bans.62  This power, however, was conferred to EPA 
under two conditions.  First, EPA must determine that the chemical in question presents 
an unreasonable risk of injury to health or the environment.  Second, according to the U.S. 
Court of Appeals for the Fifth Circuit, EPA must compare its preferred regulatory option to 
all other possible regulatory options available under TSCA and other statutes and determine 
that the net benefits of the agency’s chosen option exceed the net benefits of all other 
available options.63  Because of these judicial and statutory limitations, in TSCA’s 40-year 
history, EPA has only used § 6 to regulate five chemicals.64
EPA must determine BPA presents an unreasonable risk regardless of the severity of 
regulations it chooses to pursue, but once this determination is made it can improve its 
chances of success by tailoring the recommended regulation.  An outright ban on the 
production or use of a chemical is the most extreme action that EPA can take under § 6, 
but this would most likely face the greatest judicial scrutiny.  Other “[a]vailable restrictions 
include limiting uses or production volumes, mandating warnings, prohibiting manufacture 
or distribution, or regulating disposals.”65  Even if EPA does not feel that it can pursue an all-
out ban under § 6, it can institute less intrusive regulatory options like mandating warnings 
about the presence of BPA in base plastic materials.  Starting small, like mandating warnings, 
may help EPA overcome the judicial hurdles yet have a significant impact on worker and 
consumer awareness.  These tailored regulations, however, should not preclude EPA from 
attempting more comprehensive and stricter regulations in the future.
Occupational Safety & Health Administration
Workers who develop, construct, and use materials containing BPA are at an increased 
risk for exposure to the chemical and its negative health effects because of the frequency of 
exposure and the more direct methods of that exposure, such as inhalation and direct dermal 
absorption.66  Unfortunately, very little information about worker exposures is available.  
The best source of information is EPA’s 2006 TSCA Inventory Update, which indicates 
that more than 1000 workers were exposed to BPA at “100 to 999” U.S. worksites, and it 
was produced, stored, or used in various forms (“dry powder, pellets or large crystals, other 
solid, liquid”) at many different concentrations (the “maximum concentration” is listed as 
“greater than 90 percent”).67  These data are insufficient for regulatory purposes, much less 
communication of any meaningful information to workers about their exposure to BPA and 
the associated risks in the workplace.  
While OSHA’s purview is limited to workplace exposures, the agency could have a broad 
impact on BPA’s overall use because the “hierarchy of controls” principle of industrial 
hygiene that undergirds OSHA regulations emphasizes elimination of hazards, substitution 
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of safer products and practices, and engineering controls to prevent worker exposure—all 
strategies that could significantly reduce BPA use in products that spread from OSHA-
covered manufacturing sites throughout the marketplace.  Moreover, OSHA has a potential 
advantage over the other protector agencies because workers, the beneficiaries of OSHA’s 
efforts, can be a stronger partner in pressuring manufacturers to eliminate BPA risks than 
the general public, particularly when those workers have the strengths provided by collective 
bargaining agreements.  
As with FDA and EPA, OSHA could help eliminate risks posed by BPA exposure by first 
establishing a strong knowledge base about exposures to the chemical, then using existing 
tools (such as the Hazard Communication Standard and the OSH Act’s General Duty 
Clause) to eliminate or reduce those exposures.
Increased Scientific Research and Data Collection
As a short-term option, NIOSH and OSHA should perform more workplace studies  
and develop a more comprehensive database of workplace exposures and risks.  A 
February 2011 study and report (supported in part by NIOSH funding)68 linking male 
manufacturing workers’ low sperm counts and decreased sperm quality to high levels of 
occupational BPA exposure in China brought the public’s attention to workplace risks posed 
by the chemical in the manufacturing setting.69  When an early draft of the study first came 
to light in late 2010, it also brought attention to how we have very little publicly available 
information about U.S. workers’ exposures to the chemical.70  BPA exposure risks in the 
workplace are not limited to the manufacturing realm.  Cashiers and anyone who frequently 
handles thermal paper, like that used in store receipts, are also exposed to BPA through 
dermal absorption.71  OSHA has ready partners at NIOSH and the labor unions that can 
help the agency develop a better understanding of the occupational risks posed by BPA and 
the potential risk management options.
Part of this collaboration should include NIOSH’s Health Hazard Evaluations (HHE) 
program.72  This program encourages workers, their representatives, and managers to request 
worksite evaluations (including chemical exposure monitoring) when unregulated hazards  
or undiagnosed symptoms or illnesses present themselves.  A series of HHEs focused on 
certain industries where many workers are exposed to BPA could provide useful information 
for targeting particularly risky uses and exposure routes.
The Hazard Communication Standard
Without implementing new regulations and thus offering another short-term option, 
OSHA could ensure workers are informed about risks of occupational BPA exposure 
using the Hazard Communication (HazCom) standard.73  The standard embodies the 
principle that workers have a “right to know” about the hazards to which they are exposed 
while on the job.  It requires chemical manufacturers and importers to evaluate the hazards 
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of the chemicals they produce or import and create warning labels and material safety 
data sheets (MSDS) that will ensure that downstream users of the chemicals have access to 
information about those hazards.74  Employers must ensure that an MSDS is available to 
workers for each chemical to which they are exposed, and distributors must also transmit the 
required information to downstream employers.75  OSHA could undertake some manageable 
activities that would improve what workers know about BPA and other endocrine disrupting 
chemicals.
Though MSDSs do not follow a prescribed format they must include certain categories of 
safety information, including physical hazards and health hazards.76  The rules defining the 
health hazards that must be included in a properly formed MSDS utilize broad language, in 
furtherance of workers’ right to know about the full range of hazards they might encounter 
in the workplace.  The rules exhibit a precautionary bent, requiring hazard identification 
not only when there is clear evidence that a chemical is a carcinogen or otherwise highly 
toxic, but even when “there is statistically significant evidence based on at least one study 
conducted in accordance with established scientific principles that acute or chronic health 
effects may occur in exposed employees.”77
Under these rules, BPA’s endocrine-disrupting health hazards should be included in 
manufacturers’ MSDSs, and OSHA can ensure that happens through publication of guidance 
on the subject.  The study of workers in China that linked occupational BPA exposure 
to negative impacts on sperm quantity and quality indicates that BPA poses reproductive 
health hazards to workers that should be reported on all BPA MSDSs.  Other studies on 
laboratory animals also have identified chronic health effects.  OSHA staff should work with 
NIOSH staff to review all studies relevant to BPA’s inhalation and dermal absorption routes 
of exposure to determine whether other health hazards ought to be reported on MSDSs.  An 
example of how OSHA has taken this sort of precautionary approach in light of an emerging 
hazard is its recent actions related to the food flavoring chemical diacetyl.  When evidence 
of “popcorn workers’ lung” began to mount, OSHA published a guidance document that 
instructed manufacturers to include notifications about potential respiratory disease in all 
MSDSs covering diacetyl and other food flavorings containing the chemical.78
The ultimate problem with MSDSs lies in the conflict of interest inherent in having 
the manufacturer acting as both the evaluator of the hazard and the entity charged with 
communicating that hazard to workers, with little input and oversight from OSHA.  The 
HazCom standard’s guidance on hazard determinations does little to mandate an unbiased 
evaluation process:  under the rule, “[c]hemical manufacturers, importers, and employers 
evaluating chemicals are not required to follow any specific methods for determining 
hazards.”79  While they “must be able to demonstrate that they have adequately ascertained 
the hazards of the chemicals…in accordance with the criteria set forth in [the standard],” that 
provision seems to be insufficient in the case of BPA.
BPA’s 
endocrine-
disrupting 
health hazards 
should be 
included in 
manufacturers’ 
material safety 
data sheets 
(MSDSs).
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One need only look at The Dow Chemical Company’s MSDS for BPA to see how OSHA 
guidance would greatly improve the accuracy of health hazard communications and ensure 
that employers are meeting their duties under the HazCom standard to inform workers of 
BPA’s low-dose effects, reproductive health hazards, and the potential carcinogenic qualities.  
Dow’s MSDS for BPA states that reproductive health hazards are limited to fetal impacts 
which occur in conjunction with maternal toxicity.  In other words, Dow is only reporting 
on reproductive health hazards that occur at doses high enough to cause significant and acute 
harm to both the mother and fetus.  With mounting evidence of low-dose impacts on fetal 
development and organ function, this warning is likely insufficient, so guidance from OSHA 
would help clarify manufacturers’ duties under the HazCom standard.  BPA’s potential health 
effects from skin contact should also be revisited.  Dow’s MSDS only refers to skin irritation 
and redness resulting from prolonged or repeated contact.  However, new evidence suggests 
that BPA can be absorbed through the skin, raising concerns about cashiers’ health risks from 
exposure to the chemical through regular contact with carbonless register receipts.80 
It was precisely these deficiencies and similar ones abroad that 
spurred OSHA and the international community to develop 
The Globally Harmonized System of Classification and Labelling 
of Chemicals (GHS).81  The GHS formulated new standards and 
protocols for toxics identification, labeling, and health hazard 
communication.  In September 2009, OSHA issued a proposed 
rulemaking to amend the HazCom Standard to integrate 
GHS and make its provisions binding on American chemical 
manufacturers and workplaces.  The proposed health hazard 
standards would significantly modify MSDS requirements, 
including the establishment of a new classification system for 
reproductive toxicity.82  Hazard labeling would receive a dramatic 
overhaul as well.  While some of the newly proposed HazCom 
standards need to be reconsidered,83 many of the standards and 
MSDS requirements would provide further support for new 
guidance from OSHA on BPA.
Once the proposed rulemaking goes into effect, OSHA should 
use BPA as a model for guiding implementation of the new 
standards.  Warning labels for BPA and other endocrine-
disrupting chemicals must properly convey to workers the 
reproductive and other risks associated with low-dose exposures to the chemicals.
Permissible Exposure Limits and the General Duty Clause 
OSHA’s primary regulatory tool for limiting workers’ exposures to toxic chemicals is 
known as a Permissible Exposure Limit, or PEL.  PELs are numerical limits for airborne 
concentrations of toxic chemicals.  To set a PEL, OSHA must determine that the chemical 
What about the Consumer Products 
Safety Commission (CPSC)?
Notably missing from the list of potential 
regulators is the CPSC.  While it would seem 
that the agency in charge of consumer 
product safety would be at the forefront of 
BPA regulation, the existing CPSC regulatory 
regime and statutory limitations all but bar 
meaningful action on the part of this agency 
without an act from Congress.  Ideally, CPSC 
BPA regulations would take forms similar 
to those promulgated under the Consumer 
Product Safety Improvement Act of 2008 for 
phthalates—a group of endocrine-disrupting 
chemicals that pose similar health hazards and 
are prevalent in children’s toys and products.87  
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poses a significant risk at current exposure levels, then establish an allowable exposure level 
at which the risk will be eliminated or reduced while ensuring the standard is technologically 
and economically feasible.84  Each of these determinations requires substantial data gathering 
and analysis, none of which have been accomplished at sufficient levels for BPA.  Once the 
agency has set a PEL for a chemical, federal inspectors can sample the air at a particular 
worksite and analyze the sample to ensure that workers’ exposures are within acceptable 
levels.     
As a long-term option, OSHA needs to establish a PEL for BPA and potentially  
other endocrine disrupting chemicals that exhibit BPA’s same low-dose effects.   
There is no Permissible Exposure Limit (PEL) for BPA against which inspectors could judge 
compliance with the law, and this needs to change; however, setting a PEL for BPA is not 
a straightforward task because of BPA’s low-dose effect risks.  Even without these unique 
properties, establishing regulatory limits on a chemical under the OSH Act is not an easy 
task.  According to a recent analysis by Public Citizen’s Congress Watch division, during  
the last three decades “it has taken OSHA an average of six years to move from deciding  
to regulate a hazard to issuing a final rule.”85  The agency’s standard-setting budget is highly 
constrained (in recent years, it has amounted to less than 5 percent of OSHA’s meager $560 
million budget), and more acute under-regulated hazards with clear links to thousands of 
worker deaths (e.g., silica dust) rightly take precedence over emerging hazards.  Accordingly, 
establishing a PEL for BPA—or, preferably, endocrine disruptors as a class—is a long-term 
option for OSHA.
An alternative long-term regulatory option is to issue worker exposure regulations  
using the General Duty Clause (GDC) of the OSH Act, which requires employers  
to ensure all employees have a safe and healthy workplace.86  The GDC has been used 
to cite employers for failing to address chemical hazards in cases where employees faced 
recognized hazards that were likely to cause death or serious physical injury and a feasible 
means of abatement was available.  
The main legal sticking point for regulating BPA under the GDC would be establishing 
that workers’ exposures are likely to result in death or serious physical injury.  In general, 
OSHA can establish this element of a GDC violation by measuring worker exposures in 
excess of an Occupational Exposure Limit (OEL) that is recognized by professionals in the 
field as a threshold above which serious physical injury is likely to occur.  Organizations 
that produce such OELs include NIOSH, ACGIH, and the American Industrial Hygiene 
Association (AIHA).  However, NIOSH has not published a recommended OEL for BPA, 
nor has AIHA, and ACGIH may have abandoned its efforts to create one.87  Thus, the GDC 
option will only be available to OSHA when better occupational risk data on BPA have been 
collected and synthesized and the occupational hazards are better recognized in the relevant 
employer communities.  As EPA, FDA, OSHA, and other agencies begin to gather additional 
data and incorporate the newer studies into their regulatory programs, OSHA enforcement 
of the GDC may become a more viable option.
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Conclusion
Managing the risks posed by BPA presents fundamental challenges to the regulatory systems 
that Congress designed to protect the public and the environment from toxic chemicals.  
FDA, EPA, and OSHA are the federal agencies best poised to implement short-term 
protections, focused on data collection, hazard warnings, and information dissemination, 
but also long-term protections, focused on varying levels of use restrictions and regulatory 
safeguards.  The regulatory options and proposed action plan for EDA, EPA, and OSHA 
discussed in this paper are meant to support the actions being taken by U.S. agencies, but 
also encourage more meaningful and progressive regulation of a concerning chemical.  
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Simpson’s previous public interest experience includes internships 
with the Peace Corps Office of General Counsel and the Federal 
Public Defender’s Office in Alexandria, Virginia.  
 
 
 
 
Matthew Shudtz is a Senior Policy Analyst at the Center for 
Progressive Reform, providing research, drafting, coordination 
and other staff assistance to CPR’s Clean Science and Corporate 
Accountability Issue Groups.  Prior to joining CPR, Mr. Shudtz 
worked as a legal intern for the Natural Resources Defense Council 
and as a legal/legislative intern for the Chesapeake Bay Foundation. 
 
To see more of CPR’s work or to contribute, 
visit CPR’s website at www.progressivereform.org.
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